Avgerinou Georgia, Oikonomopoulou Christina, Kaisari Aikaterini, Ioannidou Elda, Komitopoulou Anna, Paisou Anna, Tourkantoni Natalia, Filippidou Maria, Kattamis Antonios, Vessalas George, Peristeri Ioulia, Goussetis Evgenios, Kitra Vasiliki
First Department of Pediatrics, National and Kapodistrian University of Athens, Athens, Greece.
Stem Cell Transplant Unit, Aghia Sophia Children's Hospital, Athens, Greece.
Pediatr Transplant. 2019 Feb;23(1):e13320. doi: 10.1111/petr.13320. Epub 2018 Nov 8.
aUCBT is a valuable curative option in pediatric patients with refractory idiopathic SAA and no available matched sibling or unrelated donors. Experience in the use of autologous cord blood units in patients with SAA is limited and private for-profit cord blood-banking programs are controversial. We report the successful treatment of two patients with SAA, aged 15 and 24 months, with autologous cord blood combined with immunosuppression. After conditioning with 200 mg/kg cyclophosphamide and ATG, 7.5 mg/kg, 32.2 × 10 /kg, and 3.8 × 10 /kg autologous cord blood nucleated cells were infused, respectively. One of our patients underwent transplantation after failure of IST. Both patients received post-transplant immunosuppression with cyclosporine for 12 months. They remain disease-free 6 years post-transplantation.
对于难治性特发性再生障碍性贫血且无可匹配同胞或无关供者的儿科患者,自体脐血移植(aUCBT)是一种有价值的治疗选择。在再生障碍性贫血患者中使用自体脐血单位的经验有限,并且私人盈利性脐血库项目存在争议。我们报告了两例分别为15个月和24个月大的再生障碍性贫血患者,采用自体脐血联合免疫抑制治疗获得成功。在用200mg/kg环磷酰胺和7.5mg/kg抗胸腺细胞球蛋白进行预处理后,分别输注了32.2×10⁶/kg和3.8×10⁶/kg的自体脐血有核细胞。我们的一名患者在免疫抑制治疗(IST)失败后接受了移植。两名患者移植后均接受环孢素免疫抑制治疗12个月。移植后6年,他们均无疾病复发。